The aim of this study is to evaluate the toxicity and therapeutic efficacy of erlotinib in
high-risk myelodysplastic syndrome (MDS) patients (with at least 10% of bone marrow blasts)
ineligible for or having failed intensive chemotherapy and ineligible or after failure of
treatment with a hypomethylating agent.